Vascular endothelial growth factor (VEGF) inhibition by small molecules.
作者： S.I. Ahmed , A.L. Thomas , W.P. Steward
DOI: 10.1179/JOC.2004.16.SUPPLEMENT-1.59
关键词: FLT4 、 Kinase insert domain receptor 、 Biochemistry 、 Vascular endothelial growth factor 、 Angiogenesis 、 Platelet-derived growth factor receptor 、 Vascular endothelial growth factor A 、 Cancer research 、 Chemistry 、 Receptor tyrosine kinase 、 Tropomyosin receptor kinase C
摘要: Angiogenesis is essential for primary tumours to grow and metastasise, driven by the production of positive angiogenic factors. The Vascular Endothelial Growth Factor (VEGF) family central process angiogenesis comprises 5 molecules designated A, B, C, D E. VEGF overexpressed in several solid malignancies. actions are mediated through receptors possessing tyrosine kinase activity: VEGFR-1 (Flt-1), VEGFR-2 (Kdr/Flk-1) VEGFR-3 (Flt-4). Anti-VEGF strategies include use antibodies or its receptors, ribozymes decrease receptor expression, inhibitors reduce activation downstream signalling. focus this review small molecule which target their intrinsic activity. clinical development following agents discussed: SU5416, SU11248, SU6668, PTK/ZK, ZD6474.
maneyonline.com参考文章(8)
M. Detmar, A. M. Dvorak, L. F. Brown, H. F. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. ,vol. 146, pp. 1029- 1039 ,(1995)
Corazon D. Bucana, Yasuhiko Kitadai, Karen R. Cleary, Lee M. Ellis, Yutaka Takahashi, Expression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer Cancer Research. ,vol. 55, pp. 3964- 3968 ,(1995)
A. Tolcher, J.J. O'Leary, J. DeBono, K. Molpus, C. Woodard, M. Warnat, K. Liau, D. Noe, D. Healey, M. Huberman, 137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors Ejc Supplements. ,vol. 2, pp. 44- ,(2004) , 10.1016/S1359-6349(04)80145-9
Michael J Cross, Lena Claesson-Welsh, FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition Trends in Pharmacological Sciences. ,vol. 22, pp. 201- 207 ,(2001) , 10.1016/S0165-6147(00)01676-X
Harold F. Dvorak, Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy Journal of Clinical Oncology. ,vol. 20, pp. 4368- 4380 ,(2002) , 10.1200/JCO.2002.10.088
Harold F Dvorak, Donald R Senger, Vascular permeability factor ,(1983)
Ian Zachary, Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor American Journal of Physiology-cell Physiology. ,vol. 280, pp. 1375- 1386 ,(2001) , 10.1152/AJPCELL.2001.280.6.C1375
G. D. Demetri, J. Desai, J. A. Fletcher, J. A. Morgan, C. D. M. Fletcher, A. Kazanovicz, A. Van Den Abbeele, C. Baum, R. Maki, M. C. Heinrich, SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology. ,vol. 22, pp. 3001- 3001 ,(2004) , 10.1200/JCO.2004.22.90140.3001